IHC results demonstrated significant expression of BCL2A1, CD68, and CD163 within the tumors, with BCL2A1 exhibiting a distribution pattern highly similar to that of CD68 and CD163, primarily localized in the tumor stroma region (Fig. 3A). The gene discussed is BCL2A1; the disease is neoplasm.